50 results about "Disease free survival" patented technology

This invention relates to a breakthrough method for pre-sensitizing cancer prior to a therapeutic treatment such as chemotherapy, radiation therapy or immuno-therapy and a novel cytokine mixture used in the method thereof. The cytokine mixture is a serum-free and mitogen-free mixture comprised of specific ratios of cytokines such as IL-1β, TNF-α, IFN-γ and GM-CSF to Interleukin 2 (IL-2), which is effective in inducing cancerous cells to enter a proliferative cell cycle phase thereby increasing their vulnerability to chemotherapy, radiation therapy and immuno-therapy. One such novel cytokine mixture is Multikine®, which can be used alone or in combination with other drugs for the treatment of cancer thereby increasing the success of cancer treatment and the disease free survival of cancer patients.

AnnexinA2 (ANXA2), a member of the Annexin family of calcium-dependent, phospholipid binding proteins, is one of a panel of identified antigens recognized by the post-vaccination sera of patients who demonstrated prolonged disease-free survival following multiple vaccinations. AnnexinA2 is abundantly expressed in pancreatic adenocarcinomas and cell surface / membrane AnnexinA2 increases with the progression from premalignant lesions to invasive pancreatic adenocarcinomas. The cytoplasmic to cell surface translocation of AnnexinA2 expression is critical for pancreatic cancer cell invasion. In addition, phosphorylation of AnnexinA2 at Tyrosine 23 is important for its localization to the cell surface and for the invasion of pancreatic cancer cells. Finally, loss of AnnexinA2 leads to the loss of the Epithelial-Mesenchymal Transition.

AnnexinA2 (ANXA2), a member of the Annexin family of calcium-dependent, phospholipid binding proteins, is one of a panel of identified antigens recognized by the post-vaccination sera of patients who demonstrated prolonged disease-free survival following multiple vaccinations. AnnexinA2 is abundantly expressed in pancreatic adenocarcinomas and cell surface / membrane AnnexinA2 increases with the progression from premalignant lesions to invasive pancreatic adenocarcinomas. The cytoplasmic to cell surface translocation of AnnexinA2 expression is critical for pancreatic cancer cell invasion. In addition, phosphorylation of AnnexinA2 at Tyrosine 23 is important for its localization to the cell surface and for the invasion of pancreatic cancer cells. Finally, loss of AnnexinA2 leads to the loss of the Epithelial-Mesenchymal Transition.

The invention discloses a method for quantifying a tumor immune state based on radiomics, wherein the method comprises the following steps: S1, collecting clinical information, immunohistochemical characteristics, overall survival OS and disease-free survival DFS of tumor patients; S2, obtaining a CT image sample group of solid tumors; S3, randomly dividing the patients into a training set and a test set in proportion; S4, calculating the immunoscore by an immune marker, and dividing the patients into a set with high immune state and a set with low immune state; S5, segmenting an interest region, and extracting radiomics characteristics of the solid tumors in the interest region; S6, screening the radiomics characteristics related to the immune state from the radiomics characteristics in the training set, and training a prediction model; and S7, predicting the image immunoscore of the tumor patients, obtaining the image immune state, and then predicting the DFS and the OS in the patients. The immune state of the solid tumors such as colorectal cancer, lung cancer, gastric cancer and breast cancer is predicted by the CT image characteristics, and the analysis of pathological sections and immunohistochemistry is reduced or avoided.

A method for identifying sensitivity to low-dose ionizing radiation and cancer patient prognosis. Several predictor panels of genes that are predictive for increased or decreased susceptibility for LD-induced cancer and predictor panel that are predictive for increased or decreased disease free survival in women who are newly diagnosed with breast cancer.

This invention relates to a breakthrough method for pre-sensitizing cancer prior to a therapeutic treatment such as chemotherapy, radiation therapy or immuno-therapy and a novel cytokine mixture used in the method thereof. The cytokine mixture is a serum-free and mitogen-free mixture comprised of specific ratios of cytokines such as IL-1β, TNF-α, IFN-γ and GM-CSF to Interleukin 2 (IL-2), which is effective in inducing cancerous cells to enter a proliferative cell cycle phase thereby increasing their vulnerability to chemotherapy, radiation therapy and immuno-therapy. One such novel cytokine mixture is Multikine®, which can be used alone or in combination with other drugs for the treatment of cancer thereby increasing the success of cancer treatment and the disease free survival of cancer patients.

A method for altering the composition of tumor infiltrating mononuclear cells, increasing CD4+ / CD8+ ratio, increasing tumor stroma / epithelial ratio and modulating HLA (Human Leukocyte Antigen) class II expression on a tumor cell surface with a serum-free and mitogen-free mixture having specific cytokine ratios from the group of IL-1β, TNF-α, IFN-γ, GM-CSF, and Interleukin-2 (IL-2) with specific ratios of IL-1β, TNF-α, IFN-γ, GM-CSF to IL-2, respectively. The serum-free and mitogen-free mixtures comprised of cytokine ratios include Leukocyte Interleukin Injection (LI) or Multikine®, which can be further used alone or in combination with other drugs for the treatment of cancer thereby increasing the success of cancer treatment and the disease free survival of cancer patients.

Acquired and de novo endocrine resistance are major clinical problems in the management of breast cancer patients. Though the antiestrogen tamoxifen prolongs disease-free and overall survival in the adjuvant setting, and induces remissions in over half of the patients with estrogen receptor positive metastatic disease, all patients eventually acquire tamoxifen resistance. Furthermore, many of the resistant tumors actually appear to be stimulated by tamoxifen just as they are by estrogens. The present invention provides methods of predicting endocrine resistance comprising detecting the biological activity and / or expression of p38 MAPK and / or AIB1. The invention further provides methods of reducing, reversing, or preventing endocrine resistance comprising contacting a breast or prostate tumor with a p38 MAPK pathway inhibitor.

The invention discloses a prognosis evaluation system for patients with early-stage LUAD and application thereof. According to the invention, disease-free survival data of 632 patients with early-stage LUAD in three independent queues are integrated, and an individual IBRS model for patients with early-stage LUAD is established and verified. The three independent queues include TCGA, GSE31210 and68 cases of frozen tissues. The IBRS model is composed of the following nine genes: DYNC1I2, THOC1, ADAM10, SERPINB6, CCL20, WNT2B, SLC11A1, MAPT and PSEN1. The establishment of the IBRS model for patients with early-stage LUAD is not only beneficial for understanding of the complex interaction mechanism between immune molecules, but also brings great help to the recurrence prediction of the patients with early-stage LUAD and the optimization of a treatment scheme.

This invention relates to a breakthrough method for pre-sensitizing cancer prior to a therapeutic treatment such as chemotherapy, radiation therapy or immuno-therapy and a novel cytokine mixture used in the method thereof. The cytokine mixture is a serum-free and mitogen-free mixture comprised of specific ratios of cytokines such as IL-1β, TNF-α, IFN-γ and GM-CSF to Interleukin 2 (IL-2), which is effective in inducing cancerous cells to enter a proliferative cell cycle phase thereby increasing their vulnerability to chemotherapy, radiation therapy and immuno-therapy. One such novel cytokine mixture is Leukocyte Interleukin Injection (LI) or Multikine®, which can be used alone or in combination with other drugs for the treatment of cancer thereby increasing the success of cancer treatment and the disease free survival of cancer patients.

The invention discloses an application of a 4-LncRNA molecular tag in prognosis evaluation of liver cancer. The 4-LncRNA molecular tag is used for evaluating the total survival time and the disease-free survival time of a liver cancer patient, which finds that the total survival time and the disease-free survival time of patients in a high-risk group are notably shortened as compared with patientsin a low-risk group. Besides, the prognosis evaluation value of a clinical staging system of the liver cancer can be improved by means of the 4-LncRNA molecular tag, that is, evaluation and predication of patients of the same clinical stage find that the survival time of the patients in the high-risk group is notably different from that of the patients in the low-risk group. Therefore, the 4-LncRNA molecular tag can serve as a detection marker for prognosis evaluation of liver cancer, can provide prognosis effect evaluation as well as observation and monitoring for the patients, can be used for judging the prognosis situation of the patients and has the advantages of rapidness, objectiveness, accuracy and the like.

Cancers are phenotyped by analysis of the presence of immune cells, particularly T cells and dendritic cells, present in regional lymph nodes. When non-sentinel regional lymph nodes of a cancer patient are compared to normal lymph nodes, it is found that increased number of dendritic cells and decreased numbers of T cells, particularly T helper cells, correlate with a positive prognosis and disease-free survival following conventional chemotherapy.

The invention provides methods for prognosis of patients afflicted with cancer, comprising determining the level of GP88 expression in a biological sample obtained from said patient.

The invention discloses application of gene HES2 to the auxiliary diagnosis, prognosis and treatment of esophageal squamous carcinoma. The HES2 gene is highly expressed in esophageal squamous carcinoma tissues. The experiment further discovers that mRNA of HES2 gene is highly expressed in an esophageal squamous carcinoma cell line, the progress of the HES2 high-expressed tumor is faster and is more likely to be transferred to lymph gland or far organs, which is significantly related to poor five-year disease-free survival rate and five-year general survival rate. In addition, an antisense oligonucleotide chain sequence targeting HES2 gene is also designed to silencing HES2 expression and can be useor the trd featment of esophageal cancer. HES2 can be used as a detection marker for assisting the diagnosis of the esophageal squamous carcinoma and predicting the reoccurrence trend of the esophageal squamous carcinoma as well as a treatment target spot.

The invention discloses application of circulating nucleic acid serving as a breast cancer biomarker. Via a large number of literature researches, 96 miRNAs which have differential expression in a breast cancer tissue and body fluid or have functional verification for a level of a breast cancer cell line are screened out and used as candidate genes for researching; particularly, a prognosis relationship between the circulating miRNAs and long-term follow-up people suffering from the breast cancer is researched in the application; for 182 patients, based on bivariate regression analysis of machine training, 2 to 10 miRNA combinations have a distinguishing effect on prognosis of the breast cancer patients; multi-factor Cox regression analysis shows that a combination of 2 to 7 miRNAs is used as an independent risk factor of disease free survival and distant disease free survival of the breast cancer patients; particularly in lymph node-negative patients, a combination of 4 to 5 miRNAs has a better survival forecasting effect on the low and high-risk breast cancer patients. The research provides possibility for the application of the circulating miRNA in serving as a tumor marker.

A method for altering the composition of tumor infiltrating mononuclear cells, increasing CD4+ / CD8+ ratio, increasing tumor stroma / epithelial ratio and modulating HLA (Human Leukocyte Antigen) class II expression on a tumor cell surface with a serum-free and mitogen-free mixture having specific cytokine ratios from the group of IL-1β, TNF-α, IFN-γ, GM-CSF, and Interleukin-2 (IL-2) with specific ratios of IL-1β, TNF-α, IFN-γ, GM-CSF to IL-2, respectively. The serum-free and mitogen-free mixtures comprised of cytokine ratios include Leukocyte Interleukin Injection (LI) or Multikine®, which can be further used alone or in combination with other drugs for the treatment of cancer thereby increasing the success of cancer treatment and the disease free survival of cancer patients.

The invention discloses endometrioid adenocarcinoma prognosis-related gene and protein as well as an application thereof. The invention provides a kit a to assist grouping of patients population with endometrioid adenocarcinoma, comprising a substance for detecting mRNA level expression of 21 genes: PRC1, NUSAP1, MCM6, PIWIL2, TYMS, CCNB2, ESM1, BUB1, BARD1, MCM7, CDK6, PCNA, NDC80, CCNE2, RFC4, CCNE1, SERPINA1, FOS, DUSP1, CCL20, and NR4A1. The experiment found a gene model and a protein marker capable of performing prognostic prediction of disease-free survival time of endometrioid adenocarcinoma. The model has important clinical meaning for reflecting biological characteristics of endometrioid adenocarcinoma and prognostic prediction.

The invention relates to a method for predicting recurrence and metastasis time and prognosis of a triple-negative breast cancer (TNBC) by establishing a miRNAs (micro Ribonucleic Acids) expression level. The method comprises the following steps: 1, sample collection; 2, RNA extraction and quantitative PCR (Polymerase Chain Reaction); S3, RNA sample Poly A tailing; S4, reverse transcription and quantitative PCR; S5, data analysis. As proved by the method disclosed by the invention, the expression levels of miR-4262, miR-670-3p, miR-152-3p and miR-216a-5p are remarkably relevant to disease-free survival time of 3 years and 5 years and total survival time, the recurrence and metastasis time of TNBC patients with high expression levels is often within 2 to 3 years, and the prognosis is bad. Specific treatment is performed on the part of patients, so that the recurrence and metastasis risk is lowered, and the prognosis is improved.

The invention relates to a novel method for breast cancer prognosis evaluation based on collagen distribution in a tumor microenvironment. The method comprises the steps of dividing the development ofcollagen fibers in the tumor microenvironment into three stages and eight collagen morphological distribution characteristics; performing multi-photon scanning imaging on a dewaxed breast cancer paraffin embedded tissue slice to obtain second harmonic images, namely, collagen fiber distribution images; classifying the collagen fiber distribution in each second harmonic image to obtain corresponding scores of the eight collagen distribution characteristics of the whole slice; dividing the score of each collagen morphological distribution characteristic by the total score of the eight collagendistribution characteristics to calculate the percentage of each collagen characteristic; performing cross validation by adopting ridge regression analysis, and calculating to obtain the weight of each collagen characteristic; and performing weighted sum on the percentages of the eight collagen morphological distribution characteristics and the corresponding eight weights, and calculating the final collagen distribution score of each patient, wherein the final collagen distribution score is used for judging the probability that the patient has five-year disease-free survival time. According tothe method, the postoperative risk condition of the patient can be simply, accurately and rapidly evaluated.

The present invention provides materials and methods related to CLL disease progression. The invention provides methods related to differential expression signatures, including distinguishing histological subtypes, progression patterns, poor survival patterns, and disease-free survival patterns. Antisense and sense miRNAs, kits, and other compositions, such as pharmaceutical formulations and combination therapies are also provided.

The present invention relates to prognostic methods and kits for the assessment and monitoring of relapse-free or disease-free survival of ALL patients. The detection is based on the use of detecting nucleic acids, specific for determination of the expression of at least one of miR-151-5p and miR-451 in a test sample. The invention thereby also provides methods and kits for monitoring and early diagnosis of cancerous disorders associated with low miR-151-5p and / or miR-451 expression, specifically ALL, and appropriate associated treatments thereof.

In accordance with the present invention, there are provided methods for determining a prognosis of disease free or overall survival in a patient suffering from cancer. Also provided are methods for predicting the risk of tumor recurrence or spread in an individual having a cancer tumor. Methods for screening a cancer patient to determine the risk of tumor metastasis; methods for determining the proper course of treatment for a patient suffering from cancer; and kits for use in practicing the invention methods.

The invention discloses application of 4-LncRNA molecular tags in prognosis evaluation of lung cancer. Overall survival time and disease-free survival time of lung cancer patients are evaluated through the 4-LncRNA molecular tags, and the evaluation finds that the overall survival time and disease-free survival time of patients in a high-risk group are shortened significantly when the patients inthe high-risk group are compared with patients of a low-risk group. In addition, the prognostic estimated value of a lung cancer clinical staging system can be improved through the 4-LncRNA moleculartags. In the subsequent exploration of functions and mechanisms of Lnc-GAN1 and NEAT1, the Lnc-GAN1 is found to play a cancer suppressor gene role in lung cancer, and NEAT1 is found to play a cancer suppressor gene role in lung cancer. results show that any one or a combination of two or more of the 4-LncRNA molecular tags can be used as a detection marker for the prognosis evaluation of lung cancer, prognostic effect evaluation, observation and monitor can be provided for the patients with lung cancer, and the 4-LncRNA molecular tags can be applied to judgement of the prognosis status of thepatients and other situation, and has the advantages of rapidity, objectivity, accuracy and the like.

The invention relates to the biotechnical field, and concretely relates to an application of 5-hydroxymethylcytosine and 5-formylcytosine in the preparation of a reagent or a kit for prognosis evaluation of hepatocellular carcinoma. It is found that the total genome 5hmC content and the genome 5fC content of HCC tissues are lower than those of cancer-adjacent tissues. Patients with reduced 5hmC and 5fC levels in HCC genome DNA have poor prognosis, and are prone to suffer from recurrence and metastasis. Compared with patients with high 5hmC or 5fC levels, patients with low 5hmC or 5fC levels inHCC tissues have lower disease-free survival and overall survival rates . The application provides a new prognosis evaluation method for the hepatocellular carcinoma.

The invention discloses the application of 4‑LncRNA molecular tags in the prognosis assessment of liver cancer. The present invention evaluates the overall survival time and disease-free survival time of liver cancer patients through 4‑LncRNA molecular signatures, and finds that the overall survival time and disease-free survival time of patients in the high-risk group are significantly shorter than those in the low-risk group. In addition, 4‑LncRNA molecular signatures can improve the prognostic evaluation value of the liver cancer clinical staging system, that is, to evaluate and predict patients with the same clinical stage, and find that there are significant differences in survival time between low-risk groups and high-risk patients. It shows that the 4-LncRNA molecular tag of the present invention can be used as a detection marker for liver cancer prognosis assessment, and can provide prognosis evaluation, observation and monitoring for liver cancer patients, and be used to judge the prognosis of patients, etc., and has the advantages of rapidity, objectivity and accuracy. .

The invention provides applications of GP88 combination component on manufacturing of a kit which authenticates reduced overall survival risk of a cancerous patient.

A method of assessing recurrence status in a breast cancer patient comprises a step of assaying a biological sample from the patient for a level of a biomarker selected from S100β or HOX-C1I, wherein positive detection of one or both of the biomarkers is indicative of a positive recurrence status. Suitably, the method is a method of prognosis of poor disease free survival in a breast cancer patient, wherein positive detection of one or both of the biomarkers is indicative of poor disease survival. The method may also be a method of diagnosis of recurrence, wherein positive detection of circulating S100β is a diagnostic variable of recurrence. The method of diagnosis is carried out on a patient who is undergoing first line therapy and / or a patient who has had surgery to remove a primary breast tumour.

The present invention relates to methods for determining a treatment regimen beyond surgical removal of tumor tissue for node negative or node positive breast cancer patient. The method comprises measuring the levels of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor-1 (PAI-1) in a subject, preferably a tumor; and, based upon the values, predicting the expected benefit including disease-free survival and / or overall survival for the patient without treatment (beyond the surgical removal of tumor tissue) or with a particular treatment and using that information to select a treatment regimen for the subject. High risk subject is identified by high levels of both uPA and PAI-1, high level of uPA and low level of PAI-1 or, low level of uPA and high level of PAI-1. Treatment options for high risk subjects include, but are not limited to, adjuvant CMF chemotherapy, adjuvant non-CMF chemotherapy, adjuvant endocrine therapy, adjuvant anthracyclin-containing chemotherapy, radiation therapy, and gene therapy. Treatment options for low risk subjects include, but are not limited to, no treatment, radiation, and adjuvant endocrine therapy.

The present invention relates to prognostic methods and kits for the assessment and monitoring of relapse-free or disease-free survival of ALL patients. The detection is based on the use of detecting nucleic acids, specific for determination of the expression of at least one of miR-151-5p and miR-451 in a test sample. The invention thereby also provides methods and kits for monitoring and early diagnosis of cancerous disorders associated with low miR-151-5p and / or miR-451 expression, specifically ALL.